These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7102502)

  • 1. Prolongation of verapamil elimination kinetics during chronic oral administration.
    Schwartz JB; Keefe DL; Kirsten E; Kates RE; Harrison DC
    Am Heart J; 1982 Aug; 104(2 Pt 1):198-203. PubMed ID: 7102502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of verapamil in patients with atrial fibrillation.
    Anderson P; BondessoN U; Sylvén C
    Eur J Clin Pharmacol; 1982; 23(1):49-57. PubMed ID: 7128672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verapamil disposition kinetics in chronic atrial fibrillation.
    Kates RE; Keefe DL; Schwartz J; Harapat S; Kirsten EB; Harrison DC
    Clin Pharmacol Ther; 1981 Jul; 30(1):44-51. PubMed ID: 7237897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced verapamil clearance during long-term oral administration.
    Shand DG; Hammill SC; Aanonsen L; Pritchett EL
    Clin Pharmacol Ther; 1981 Nov; 30(5):701-6. PubMed ID: 7297027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verapamil kinetics during maintenance hemodialysis.
    Shah GM; Winer RL
    Am J Nephrol; 1985; 5(5):338-41. PubMed ID: 4061502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation of the cause of accumulation of verapamil during regular dosing in patients.
    Schwartz JB; Abernethy DR; Taylor AA; Mitchell JR
    Br J Clin Pharmacol; 1985 Apr; 19(4):512-6. PubMed ID: 3994898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.
    McAllister RG; Kirsten EB
    Clin Pharmacol Ther; 1982 Apr; 31(4):418-26. PubMed ID: 7060323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of verapamil in patients with hypertension.
    Anderson P; Bondesson U; de Faire U
    Eur J Clin Pharmacol; 1986; 31(2):155-63. PubMed ID: 3803414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing.
    Busse D; Fromm MF; Mörike K; Drescher S; Kühlkamp V; Eichelbaum M
    Clin Pharmacol Ther; 2001 May; 69(5):324-32. PubMed ID: 11372000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of verapamil and norverapamil in human biological material. Investigation of plasma concentrations after oral administration of two different verapamil formulations.
    Horne C; Spahn H; Mutschler E; Knauf H
    Arzneimittelforschung; 1987 Aug; 37(8):956-9. PubMed ID: 3675692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits.
    Siegner SW; Giovanoni RL; Erickson KA; Netland PA
    J Ocul Pharmacol Ther; 1998 Apr; 14(2):159-68. PubMed ID: 9572542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation.
    Lang R; Klein HO; Weiss E; David D; Sareli P; Levy A; Guerrero J; Di Segni E; Kaplinsky E
    Chest; 1983 Mar; 83(3):491-9. PubMed ID: 6337787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment.
    Piovan D; Padrini R; Svalato Moreolo G; Magnolfi G; Milanesi O; Zordan R; Pellegrino PA; Ferrari M
    Ther Drug Monit; 1995 Feb; 17(1):60-7. PubMed ID: 7725379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog.
    Hamann SR; Todd GD; McAllister RG
    Pharmacology; 1983; 27(1):1-8. PubMed ID: 6611645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
    Barbieri E; Padrini R; Piovan D; Toffoli M; Cargnelli G; Trevi G; Ferrari M
    Int J Clin Pharmacol Res; 1985; 5(2):99-107. PubMed ID: 4018947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of verapamil in patients with renal failure.
    Mooy J; Schols M; v Baak M; v Hooff M; Muytjens A; Rahn KH
    Eur J Clin Pharmacol; 1985; 28(4):405-10. PubMed ID: 4029246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.
    Dadashzadeh S; Javadian B; Sadeghian S
    Biopharm Drug Dispos; 2006 Oct; 27(7):329-34. PubMed ID: 16892180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB
    Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of racemic verapamil in patients with impaired renal function.
    Zachariah PK; Moyer TP; Theobald HM; Frantz RP; Kurtz SB; McCarthy JT; Smith RL
    J Clin Pharmacol; 1991 Jan; 31(1):45-53. PubMed ID: 2045528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of oral verapamil therapy on antipyrine clearance.
    Rumiantsev DO; Piotrovskii VK; Riabokon OS; Slastnikova ID; Kokurina EV; Metelitsa VI
    Br J Clin Pharmacol; 1986 Nov; 22(5):606-9. PubMed ID: 3790408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.